Baseline (BL) characteristics, treatment (tx) patterns, and outcomes in patients with hormone receptor (HR) plus vs HR-HER2+disease from the SystHERs registry

Cobleigh, M; Yardley, DA; Brufsky, A; Rugo, H; Swain, S; Kaufman, PA; Tripathy, D; Mayer, M; Hurvitz, S; O'Shaughnessy, J; Mason, G; Chu, L; Antao, V; Beattie, M; Yoo, B; Jahanzeb, M

CANCER RESEARCH, 2017; 77 ( ):